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Abstract

Background Gentamicin has historically been used prior to insertion and removal of indwelling urinary
catheters (IDCs) around elective joint replacement surgery to prevent infection; however, this indication is
not recognized in the Australian Therapeutic Guidelines: Antibiotic and the paradigm for safe use of gentamicin
has shifted.
Methods The antimicrobial stewardship team of a 500 bed tertiary regional hospital performed a
retrospective clinical study of gentamicin IDC prophylaxis around total hip and knee arthroplasties. Results
were presented to the orthopaedic surgeons. A literature review identified no guidelines to support gentamicin
prophylaxis and only a very low risk of bacteraemia associated with IDC insertion/removal in patients with
established bacteriuria. Consensus was reached with the surgeons to discontinue this practice. Subsequent
prospective data collection was commenced to determine effectiveness, with weekly feedback to the
Department Head of Orthopaedics.
Results Data from 137 operations pre-intervention (6 months) were compared with 205 operations postintervention (12 months). The median patient age was 72 years in both groups. Following the intervention,
reductions in gentamicin use were demonstrated for IDC insertion (59/137 (42%) to 4/205 (2%), P < 0.01)
and removal (39/137 (28%) to 6/205 (3%), P < 0.01). No gentamicin use was observed during the final 40
weeks of the post-intervention period. There were no significant differences between the groups for preoperative bacteriuria, surgical site infections or acute kidney injury.
Conclusion A collaborative approach using quality improvement methodology can lead to an evidence-based
reappraisal of established practice. Regular rolling audits and timely feedback were useful in sustaining change.
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Abstract
Background:
Gentamicin has historically been used prior to insertion and removal of indwelling urinary
catheters (IDCs) around elective joint replacement surgery to prevent infection; however, this
indication is not recognised in the Australian Therapeutic Guidelines: Antibiotic and the
paradigm for safe use of gentamicin has shifted.
Methods:
The antimicrobial stewardship team of a 500 bed tertiary regional hospital performed a
retrospective clinical study of gentamicin IDC prophylaxis around total hip and knee
arthroplasties. Results were presented to the orthopaedic surgeons. A literature review
identified no guidelines to support gentamicin prophylaxis and only a very low risk of
bacteraemia associated with IDC insertion/removal in patients with established bacteriuria.
Consensus was reached with the surgeons to discontinue this practice. Subsequent
prospective data collection was commenced to determine effectiveness, with weekly
feedback to the Department Head of Orthopaedics.
Results:
Data from 137 operations pre-intervention (6 months) were compared with 205 operations
post-intervention (12 months). The median patient age was 72 years in both groups.
Following the intervention, reductions in gentamicin use were demonstrated for IDC insertion
(59/137 [42%] to 4/205 [2%], p<0.01) and removal (39/137 [28%] to 6/205 [6%], p<0.01). No
gentamicin use was observed during the final 40 weeks of the post-intervention period.
There were no significant differences between the groups for pre-operative bacteriuria,
surgical site infections or acute kidney injury.
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Conclusion:
A collaborative approach using quality improvement methodology can lead to an evidence
based reappraisal of established practice. Regular rolling audits and timely feedback were
useful in sustaining change.
Word Count: Abstract 248 words; Main text 3496 words (including abstract, 500 words for 2
tables and 500 words for 2 figures, excluding references [882 words])
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Introduction
Urinary catheterisation is common during the peri-operative period and is associated with
increased risk of bacteriuria and symptomatic urinary tract infection (UTI).1 In contrast,
bacteraemia from indwelling urinary catheter (IDC) manipulation is rare, even when
indwelling times are longer.2-4 A causal link has not been established between peri-operative
asymptomatic bacteriuria, bacteraemia and subsequent haematogenous seeding of the
prosthetic joint.5 Studies have reported either no effect 6 or modest reduction7-13 in rates of
bacteriuria and UTIs from antibiotic prophylaxis around short term IDC use. Several
limitations applied: small sample sizes, none examined aminoglycosides, and the effect on
antibiotic resistance was not routinely examined. In addition, the studies were not performed
in the setting of orthopaedic surgery, and did not examine the impact on surgical site
infections (SSIs).
Gentamicin is an aminoglycoside antibiotic administered intravenously for the
treatment of Gram-negative infections.14 Gentamicin is also recommended as prophylaxis for
surgery with high risk of Gram-negative infections, such as urological procedures.15 Due to
concerns over side effects such as ototoxicity and nephrotoxicity, with even after a single
dose,16, 17 there has been a shift in the paradigm of safe gentamicin use.18 Two recent
studies examining the combination of gentamicin with a beta-lactam antibiotic for
orthopaedic surgical prophylaxis gave conflicting results on the risk of acute kidney injury
(AKI).19, 20 Both highlighted the presence of additional potentially nephrotoxic factors (e.g.
older age, fractures, volume loss, anti-hypertensive medications and analgesics).
The Australian Therapeutic Guidelines: Antibiotic15 recommend against the routine
use of gentamicin in the setting of peri-operative IDC insertion and removal and this
recommendation has not changed in the latest update.21 Despite guideline
recommendations, gentamicin had been used as peri-operative prophylaxis in around one
third of orthopaedic patients in our hospital. Some surgeons were initially reluctant to
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abandon gentamicin use, due to concerns about a potential increase in SSI rates and
medico-legal considerations related to not following an established historical practice.
Education and quality improvement are fundamental aspects of antimicrobial
stewardship (AMS) in hospitals. 22 Recent evidence suggests that feedback as a component
of the change management process is more effective when it is: frequently presented;
delivered by a peer; and aims to decrease a specific behaviour. 23 Our study analysed the
effect of education with rapid-cycle audit and feedback, a method that may be effective
where clinicians have previously agreed to review their practice.24 The importance of
engaging with stable staff groups such as consultant surgeons and anaesthetists became
evident. We assessed the impact of a group of interventions that aimed to reduce
prophylactic gentamicin use during IDC insertion and removal in orthopaedic surgery,
without increasing SSI rates. We aspired that this quality improvement initiative could
constitute an effective model for management of change in the setting of limited background
data.
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Methods
Setting
We initially performed a retrospective clinical study at Wollongong Hospital, a regional 500
bed university teaching hospital in New South Wales (NSW), Australia. The antimicrobial
stewardship (AMS) team (pharmacist and infectious diseases physician) identified the use of
gentamicin as prophylaxis for IDC insertion and removal during a routine retrospective audit
of systemic antibiotic prophylaxis around total hip and knee arthroplasties and revisions. IDC
use was routine in this setting. The decision to administer gentamicin and its dose were at
the discretion of the surgeon and there was not a departmental policy.
Intervention
This study employed Plan, Do, Study, Act (PDSA) quality improvement methodology25. The
timeline of observations and interventions is shown in Figure 1. The guideline
recommendations for routine surgical prophylaxis were the same for both the pre- and postintervention groups (cephazolin routinely, with or without vancomycin following risk
assessment for methicillin-resistant Staphylococcus aureus [MRSA]).15 Notably, there was
discussion with the surgeons and anaesthetists around guideline-concordant prescribing
during the time interval (March 2012 to January 2013) from the presentation of initial findings
until the main intervention point. Discussion also occurred at the AMS committee meetings
(which included a surgeon representative) during this time.
SSIs were defined according to standard definitions26 and reported by mandate to the
NSW Ministry of Health. AKI was defined by the Kidney Disease Improving Global Outcomes
criteria as a >50% rise above baseline serum creatinine.27 Assessment for vestibular toxicity
was available, as dictated by patient symptoms.

7

Outcomes
The effect of the intervention was assessed using the following measures: prevalence of
gentamicin use for insertion and removal of IDCs; comparative SSI rates; proportion of
patients with AKI 48-72 hours post-operation.
Data sources
A retrospective dataset of total hip and total knee arthroplasties was obtained from medical
records for the period 1 January to 30 June 2011. Gentamicin use was assessed from
anaesthetic and medication charts, and serum creatinine measurements were retrieved from
the electronic medical record (eMR; Cerner Powerchart™). Arthroplasty data were collected
prospectively during the post-intervention period (February 2013 to February 2014) from the
eMR and ward list. The infection control service provided SSI rates.
Statistical analyses
Statistical analyses were performed using Stata statistical software: Release 14 (Statacorp
LP, College Station, TX, USA). Chi-square and Fisher’s exact tests were used as
appropriate. A Shapiro-Wilk test was used to check for normal distribution, and MannWhitney U-test was used for continuous variables. Statistical significance was accepted as
p<0.05.
Ethics
This study was approved by the University of Wollongong and Illawarra Shoalhaven Local
Health District Human Research Ethics Committee: HE11/103.
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Results
Data from 137 operations pre-intervention (6 months, retrospective) were compared with 205
operations post-intervention (12 months, prospective; Table 1). Patient age and weight were
similar in both groups; however, there were marginally more males in the post-intervention
sample (31% vs. 42%, p=0.048). There were more positive pre-operative MRSA screening
cultures in the pre-intervention group (3% vs. 0.5%, p=0.047). No differences were observed
in the number of positive pre-operative urine samples (Table 1). Gentamicin doses ranged
from 80mg to 240mg.
A significant reduction in gentamicin use was demonstrated post-intervention (Table
2). From week 12 of the post-intervention period (Figure 2), no further doses of gentamicin
were administered for IDC manipulation.
No significant differences were found between the numbers of superficial hip, deep
hip, superficial knee, or deep knee infections (Table 2). There were no significant changes in
the rates of AKI, (Table 2) and no reports of vestibular toxicity following gentamicin use.
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Discussion
Our study showed that a combined intervention of education and discussion with audit and
timely feedback was effective in withdrawing the practice of prophylactic gentamicin for IDC
insertion and removal in orthopaedic surgery. No significant changes were observed in the
rates of SSI or AKI, although the study was not powered adequately to detect those. Most
importantly, this study offers a model for a sustained quality improvement initiative in the
setting of limited background data and contributes to emerging evidence on the beneficial
role of AMS in improving antibiotic use.
The majority of infections in orthopaedic surgery are caused by Gram-positive skin
flora, for which cephazolin and vancomycin (where appropriate) provide adequate
prophylaxis.15 The potential risks and lack of clinical benefit from gentamicin in this setting
formed the basis of our intervention. Rates of gentamicin use were reducing during the
planning and discussion period, highlighting that the ongoing interaction resulted in gradual
practice change. This was consolidated to a withdrawal of gentamicin prescribing in the
study sample. The importance of directly addressing medico-legal concerns and providing
written support for practice change was also recognised.
To our knowledge, this is the first study that has examined the impact of a change to
IDC prophylaxis on clinical outcomes for orthopaedic surgery patients. A Cochrane review of
antibiotic prophylaxis for short term IDC bladder drainage in adults showed that the primary
outcome of bacteriuria was lower in the prophylaxis group.28 There is no evidence linking
insertion and/or removal of an IDC with Gram-negative bacteraemia and seeding of a newly
implanted prosthesis. Although a recent study has demonstrated that asymptomatic
bacteriuria was an independent risk factor for prosthetic joint infection, preoperative antibiotic
treatment did not show any benefit and infecting organisms were frequently different to those
isolated prior to surgery.5 Studies reporting bacteraemia from IDCs in the setting of chronic
catheterisation reported low rates of established infection.2-4
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There were no deep SSIs during the pre-intervention period and only one (0.5%)
post-intervention. During the intervening period the SSI rate was low at 1.1%, comparable
with existing literature.29, 30 These differences were not statistically significant. Studies
powered to detect changes in SSI rates typically require larger sample sizes.29-31
The rate of peri-operative AKI in our study was 1-2%. Rates have been previously
reported at 11% for orthopaedic surgeries with routine gentamicin prophylaxis, but with
different gentamicin doses.19 The lower rate in our study may be due to the lower doses of
gentamicin for IDC prophylaxis than for routine skin prophylaxis.
A focus on immediate clinical outcomes (gentamicin toxicity) rather than parameters
that appear later (antibiotic resistance) may have stronger influence on prescribing
behaviour.32 Other strategies to reduce the risk of IDC-related UTI in the peri-operative
setting include: intermittent or no catheterisation, early mobilisation (that shortens the period
when the IDC needs to remain in place), training for insertion techniques, good IDC care and
consideration of IDC materials.33 Male patients receiving epidural anaesthesia may be at
greater risk of urinary retention in the setting of orthopaedic surgery.34-36
There were several limitations to our study. These included confounding factors that
may influence SSI rates (skin preparation, surgical technique, patient comorbidities) and the
significantly larger proportion of male patients in the post-intervention sample (probably
resulting from variation in data collection methods). The study was not powered to detect
changes in SSI rates and those were not followed up long term, meaning that late deep
infections may have been missed. The indication for gentamicin use was not routinely
documented on the anaesthetic records and drug charts. The study did not follow the
prescribing habits of individual surgeons, so some of the change in gentamicin use may
have been due to changes in staff. There were; however, minimal staff changes at a senior
level during study period. We believe that interpersonal interactions, the prevailing local
culture of quality improvement and strong leadership of the units involved have contributed
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to the successful outcomes of this study. Those features were furthermore strengthened
during the interactive audit and feedback process; generalisability to other settings needs to
be tested. Audiometry was not available on site to test for gentamicin toxicity. Although we
used a methodology common in pragmatic AMS research, introduction of bias may be
inherent, outside a randomised controlled environment.
In conclusion, we have shown that a group of robust multi-disciplinary AMS
interventions effected durable practice change without obvious evidence of harm. Further
studies are required to demonstrate validity in other settings, as well as the impact of
gentamicin prophylaxis on renal function in other types of surgery.
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Table 1 Patient characteristics and pre-operative screening
Pre-intervention

Post-intervention

p value

72 (40-91)

72 (35-87)

0.79

43 (31)

86 (42)

0.048

82 (40-142)

82 (44-143)

0.79

116/137 (87)

188/205 (92)

0.13

Hip arthroplasty§, n (%)

58/137 (42)

70/205 (34)

0.13

MRSA screening swab

4/122 (3)

1/204 (0.5)

0.047

25/123 (20)

28/198 (14)

0.15

11/25 (44)

8/28 (29)

0.24

Median age, yrs
(range)
Male, n (%)
Median weight†, kg
(range)
Cephazolin as skin
prophylaxis‡, n (%)

positive
Pathogen isolated in
pre-operative urine
sample║, n (%)
Pre-op positive urines
treated with
antibiotics║, n (%)
†

‡

Data available from 133 patients pre-intervention; 202 post-intervention; Data available from 134 patients pre§

║

intervention, 205 post-intervention; Includes revisions; Includes mixed and single pathogen growth. The
remainder of the urine samples were reported as “no growth” or “no significant growth”.
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Table 2 Gentamicin use, surgical site infections and acute kidney injury, n (%)
Pre-intervention

Discussion and

Post-intervention

(6 months)

planning period

(12 months)

n = 137

(20 months)

n = 205

p value

n = 605
Gentamicin for

59 (42)

N/A

4 (2)

<0.01

39 (28)

N/A

6 (3)

<0.01

0 (0)

7 (1.2)

1 (0.5)

0.59

1 (0.7)

3 (0.5)

0 (0)

0.45

2 (2)

N/A

1 (1)

0.35

IDC insertion
Gentamicin for
IDC removal†
Surgical site
infections, deep
Surgical site
infections,
superficial
Post-operative
acute kidney
injury‡
†

‡

Data available from 137 patients pre-intervention, 204 patients post-intervention defined as >50% rise in

baseline serum creatinine
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Figure Legends

Figure 1 Timeline of observations and interventions
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Figure 2 The proportion of patients receiving gentamicin for catheter insertion and removal over the 6 month preintervention period and during each week post-intervention. The discussion and planning period is shown in grey.
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